Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

Abstract

OBJECTIVES:The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD).METHODS:We prospectively evaluated CD patients enrolled in the large, observational Crohn's Therapy, Resource, Evaluation, and Assessment Tool registry, established to compare infliximab safety with conventional nonbiological medications in CD.RESULTS:A total of 6,273 patients were enrolled and evaluated on or before 23 February 2010; 3,420 received infliximab (17,712 patient-years; 89.9% received ≥2 infusions) and 2,853 received other-treatments-only (13,251 patient-years). Mean length of patient follow-up was 5.2 years. More infliximab- than other-treatments-only-treated patients had moderate-to-severe (30.6% vs. 10.7%) or severe-to-fulminant (2.5% vs. 0.6%) disease severity (P<0.001). In the year before enrollment, more infliximab- than other-treatments-only-treated patients required surgical intervention (17.4% vs. 13.6%), medical hospitalization (14.2% vs. 8.8%), prednisone (47.8% vs. 31.4%), immunomodulators (52.0% vs. 32.1%), and narcotic analgesics (17.3% vs. 9.1%). Patient mortality was similar for infliximab- and other-treatments-only-treated patients (0.58 vs. 0.59/100 patient-years). In multivariate logistic regression analyses, treatment with prednisone (hazard ratio (HR)=2.14, 95% confidence interval (CI)=1.55, 2.95; P<0.001) or narcotic analgesics (HR=1.79, 95% CI=1.29, 2.48; P<0.001) and age (HR=1.08, 95% CI=1.07, 1.09; P<0.001) were associated with increased mortality risk. Neither infliximab nor immunomodulator treatment was associated with increased mortality risk. Factors independently associated with serious infections included moderate-to-severe disease activity (HR=2.24, 95% CI=1.57, 3.19; P<0.001), narcotic analgesic treatment (HR=1.98, 95% CI=1.44, 2.73; P<0.001), prednisone therapy (HR=1.57, 95% CI=1.17, 2.10; P=0.002), and infliximab treatment (HR=1.43, 95% CI=1.11, 1.84; P=0.006).CONCLUSIONS:Mortality was similar between infliximab- and other-treatments-only-treated CD patients. An increased risk of serious infection with infliximab was observed, although CD severity and use of prednisone or narcotic analgesics carried higher risks.

Addressing current treatment challenges in Crohn's disease in real life: A physician's survey

“…Even after extensive world-wide experience with anti-TNF-therapy in IBD and other indications, such as rheumatological or dermatological diseases, there still is some uncertainty about potential risks [9][10][11][12][13] . In the last few years, there has been an increasing trend towards an earlier introduction of TNF-inhibitors (which is associated with a better efficacy 14 ) either via a rapid step up 15,16 or top down 17 , to avoid prolonged steroid exposure and minimizing CDassociated morbidity and the need for surgery.…”

Hydroxylases as therapeutic targets in inflammatory bowel disease

“…19 However, early use of therapeutic antibodies, typically combined with immunomodulators to promote mucosal healing may also lead to increased risk of toxicity, infections and the rare risk of hepatosplenic T-cell lymphoma in young men. [20][21][22] While current therapeutic approaches reduce disease activity and improve symptoms, the degree to which sustained mucosal healing has been achieved has been disappointing in randomized-controlled trials in both ulcerative colitis and Crohn's disease. 23 A number of key limitations still exist with current therapeutic options.…”

New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease

“…However, the greatest focus has been on infections, malignancy, and immune-mediated diseases. [8][9][10] Drug-induced liver injury (DILI) may range from minor elevation of transaminases to acute liver failure and even death. Liver enzyme elevations are included as safety concerns in the medication package insert.…”